In summary, we have identified the PARG inhibitor ethacridine as a novel combination candidate for erlotinib in AML. Erlotinib synergizes with ethacridine by potentiating its intracellular accumulation; however, the mechanism by which ethacridine accumulates in TEX and OCI-AML2 cells remains to be elucidated. The potential impact of PARG inhibition as a therapeutic strategy in AML warrants further investigation.

Erlotinib synergizes with the poly (ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells

DATTI, Alessandro
Supervision
;
2016

Abstract

In summary, we have identified the PARG inhibitor ethacridine as a novel combination candidate for erlotinib in AML. Erlotinib synergizes with ethacridine by potentiating its intracellular accumulation; however, the mechanism by which ethacridine accumulates in TEX and OCI-AML2 cells remains to be elucidated. The potential impact of PARG inhibition as a therapeutic strategy in AML warrants further investigation.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11391/1399982
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact